塞费皮姆诱导的神经毒性的趋势:系统性审查
Oluwafemi Ajibola1, Taiwo O Aremu2,3,4, Stephen O Dada5
1Pulmonary and Critical Care Medicine, Louisiana State University Health Sciences Center, New Orleans, USA.
Cureus
|July 28, 2023
概括
报告说,塞费皮姆诱导的神经毒性增加了,特别是在老年人中. 在患有功能障碍的患者中,适当调整塞费皮姆的剂量对于预防神经毒性至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
- 传染性疾病 传染性疾病
背景情况:
- 由于对万科米辛和Zosyn脏毒性的担忧,Cefepime的使用增加.
- 塞费皮姆虽然有效,但具有神经毒性风险.
- 越来越需要了解cefepime诱导的神经毒性趋势.
研究的目的:
- 系统地审查和分析过去十年中塞费皮姆诱导的神经毒性的趋势.
- 为了确定患者的人口统计,适应症和与cefepime神经毒性相关的危险因素.
- 评估患有功能障碍的患者的塞费皮姆剂量实践.
主要方法:
- 在线医学文献的系统审查.
- 包括46篇文章报告了73个Cefepime诱导的神经毒性病例.
- 对从2013年到2022年的病例报告进行分析.
主要成果:
- 从2013年到2022年,报告的塞费皮姆神经毒性病例的持续增加.
- 65岁以上的患者占神经毒性病例的52%.
- 常见的适应症:骨/关节感染,尿道感染,肺炎;功能障碍患者经常缺乏剂量调整.
结论:
- 塞费皮姆的神经毒性是越来越令人担忧的,特别是在老年人中.
- 不充分的脏剂量调整是显著的危险因素.
- 在功能障碍中优化塞费皮姆剂量对于患者的安全至关重要.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
464
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
464
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
346
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
346
Electroconvulsive Therapy
69
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
69


